At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
TTHX1114(NM141) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/ Phase 2 Study Evaluating the Safety and Efficacy of the Investigational New Drug TTHX1114(NM141) on the Regeneration of Corneal Endothelial Cells in Patients With Corneal Endothelial Dystrophies Following Intracameral Delivery
In Brief
A Phase 2 clinical trial evaluating TTHX1114(NM141) and Vehicle (placebo) for Corneal Endothelial Dystrophy and 3 related conditions. Completed, enrolled 22 participants across 8 sites.
Detailed Summary
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedAug 2020
Primary CompletionApr 2021
Study CompletionMay 2021
TodayJul 2026
First PostedAug 20, 2020
Enrollment StartAug 19, 2020
Primary CompletionApr 23, 2021
Study CompletionMay 18, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.9 years ago
Interventions
TTHX1114(NM141)drug
engineered FGF-1 delivered intracamerally
Vehicle (placebo)other
Placebo